0000000000391244

AUTHOR

Gerlinde F. Plöger

showing 2 related works from this author

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Cephalexin Monohydrate.

2019

Literature data and results of experimental studies relevant to the decision to allow waiver of bioequivalence studies in humans for the approval of immediate release solid oral dosage forms containing cephalexin monohydrate are presented. Solubility studies were performed in accordance with the current biowaiver guidelines of the Food and Drug Administration, World Health Organization and European Medicines Agency, taking the degradation at some pH values into consideration. Together with solubility and permeability data for cephalexin monohydrate from the literature, it was demonstrated to be a Biopharmaceutics Classification System Class 1 drug. The pharmacokinetic behavior, results of b…

Drugmedia_common.quotation_subjectPharmaceutical ScienceExcipientAdministration OralBiological Availability02 engineering and technologyBioequivalencePharmacology030226 pharmacology & pharmacyDosage formPermeabilityBiopharmaceutics03 medical and health sciences0302 clinical medicinemedicineBiopharmaceutics Classification System (BCS)HumansRegulatory scienceLADME characteristicsmedia_commonActive ingredientcephalexin monohydrateDosage FormsbioequivalenceCephalexinexcipientsbusiness.industryBiopharmaceutics021001 nanoscience & nanotechnologyBiopharmaceutics Classification SystemSolubilityTherapeutic Equivalencyregulatory science0210 nano-technologybusinessmedicine.drugJournal of pharmaceutical sciences
researchProduct

Biowaiver Monographs for Immediate Release Solid Oral Dosage Forms: Proguanil Hydrochloride

2018

Abstract Literature data relevant to the decision to waive in vivo bioequivalence testing for the approval of generic immediate release solid oral dosage forms of proguanil hydrochloride are reviewed. To elucidate the Biopharmaceutics Classification System (BCS) classification, experimental solubility and dissolution studies were also carried out. The antimalarial proguanil hydrochloride, effective via the parent compound proguanil and the metabolite cycloguanil, is not considered to be a narrow therapeutic index drug. Proguanil hydrochloride salt was shown to be highly soluble according to the U.S. Food and Drug Administration, World Health Organization, and European Medicines Agency guide…

DrugCycloguanilProguanilmedia_common.quotation_subjectProguanil HydrochlorideAdministration OralPharmaceutical SciencePharmacologyBioequivalence030226 pharmacology & pharmacyDosage formExcipientsAntimalarials03 medical and health sciences0302 clinical medicineparasitic diseasesAnimalsHumansMedicineRegulatory sciencemedia_commonDosage Formsbusiness.industryBiopharmaceutics Classification SystemMalariaProguanilSolubilityTherapeutic Equivalency030220 oncology & carcinogenesisbusinessmedicine.drugJournal of Pharmaceutical Sciences
researchProduct